CVS Health Corp. Received Low Stock Rating By Vetr Inc
Downward deviation is observed by Vetr Inc. in CVS Health Corporation stock and states further recommendations by many other analysts.
According to Vetr analysis, CVS Health Corp. (NYSE: CVS) received the downgraded rating from a Strong Buy rating to Buy rating during a research note introduced to the financial investors on Thursday. This news was broadcasted by the website Marketbeat.com.
Currently, the company stood at the price target of $117.77 on the pharmacy operator’s stock. The recommended price target by Vetr’s mentioned that it would rise up to around 11.95% from its past closing.
Several analysts put forward their recommendations on the basis of their survey and research on CVS stock and placed it on the scale. FBR & Co. heightened their price target on the shares to $120 from $110 and suggested an “outperform” rating in a research note on June 16, Tuesday.
According to the Macquarie’s coverage on the shares of Health Corp on June 9, Tuesday, they also recommended an “outperform” rating and higher target price of $115 on the stock. On June 26, Friday, Oppenheimer polled its coverage on CVS Health and suggested the price target of $119.00 along with the “outperform” rating to the company. Similarly, on June 23, Tuesday, in a research note, Cowen and Company reestablished their target price at $116 and suggested the rank with the “outperform” rating.
With respect to the Zacks analysis, the company’s shares slid from Buy rating to a Hold rating during a research note on May 20, Monday. Four equities research professionals have put forward the stock with the Hold rating. 18 researchers offered a Buy rating. One analyst has assigned Strong Buy to the stock. The organization is currently positioned at estimation of Buy and evaluated average target price of $114.75.
CVS health traded with 2.26% raise on Thursday throughout the midday trading, hitting the peak of $105.20. The company had a collective trading volume of 6,216,224 shares and market capitalization of $117.61 billion with the price earnings ratio of 25.44. Its 50-day moving average is around $108.51 and its 200-day moving average is $104.14.
The company suffered from 52-week low of $77.40 and survived smoothly with the 13-months high of $113.65. The corporation revealed its quarterly result on August 4, in which it reports $1.22 per share earnings with the revenue of $37.20 billion throughout the quarter.
CVS manages an established business that can be vulnerable to any negative variation in stock or ratings. This would lead to criticism that can injure the credibility and integrity of the company in the corporate market.